The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report

Ahmed Badran; Clara Steele; Hisham Alquaydheb; Ahmed Ba Theeb; Abdulmalek Bawazir; Mahmoud A. Elshenawy; Jean Paul Atallah

doi:10.1159/000532099

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report

Ahmed Badran, Clara Steele, Hisham Alquaydheb, Ahmed Ba Theeb, Abdulmalek Bawazir, Mahmoud A. Elshenawy, Jean Paul Atallah

Internal Diseases

Research output: Contribution to journal › Article › peer-review

Abstract

Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid fibrosarcoma refractory to all traditional treatment options.

Original language	English
Pages (from-to)	746-752
Number of pages	7
Journal	Case Reports in Oncology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1159/000532099
State	Published - 28 Aug 2023

Keywords

Anaplastic lymphoma kinase mutation
Crizotinib
Sclerosing epithelioid fibrosarcoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000532099

Cite this

@article{96d8e0a7c10840179d801794e063918c,

title = "The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report",

abstract = "Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid fibrosarcoma refractory to all traditional treatment options.",

keywords = "Anaplastic lymphoma kinase mutation, Crizotinib, Sclerosing epithelioid fibrosarcoma",

author = "Ahmed Badran and Clara Steele and Hisham Alquaydheb and \{Ba Theeb\}, Ahmed and Abdulmalek Bawazir and Elshenawy, \{Mahmoud A.\} and Atallah, \{Jean Paul\}",

year = "2023",

month = aug,

day = "28",

doi = "10.1159/000532099",

language = "English",

volume = "16",

pages = "746--752",

journal = "Case Reports in Oncology",

issn = "1662-6575",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation

T2 - A Case Report

AU - Badran, Ahmed

AU - Steele, Clara

AU - Alquaydheb, Hisham

AU - Ba Theeb, Ahmed

AU - Bawazir, Abdulmalek

AU - Elshenawy, Mahmoud A.

AU - Atallah, Jean Paul

PY - 2023/8/28

Y1 - 2023/8/28

N2 - Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid fibrosarcoma refractory to all traditional treatment options.

AB - Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid fibrosarcoma refractory to all traditional treatment options.

KW - Anaplastic lymphoma kinase mutation

KW - Crizotinib

KW - Sclerosing epithelioid fibrosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85170532758&partnerID=8YFLogxK

U2 - 10.1159/000532099

DO - 10.1159/000532099

M3 - Article

AN - SCOPUS:85170532758

SN - 1662-6575

VL - 16

SP - 746

EP - 752

JO - Case Reports in Oncology

JF - Case Reports in Oncology

IS - 1

ER -

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this